Evidence
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.
ABSTRACT
Alzheimer’s disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.
PMID:38246483 | DOI:10.1016/j.mcpro.2024.100721
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
🌐 90 Days
VR Related Evidence Matrix
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer's Disease Brain
- Integration of Microfluidic Devices with Microelectrode Arrays to Functionally Assay Amyloid-β-Induced Synaptotoxicity
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- Proteomics Impact on Cell Biology to Resolve Cell Structure and Function
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity
- Memantine versus Ginkgo biloba Extract: A Comparative Study on Cognitive Dysfunction Treatment in a Novel Rat Model
- Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model
- The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease
- TDP-43 and Alzheimer's Disease Pathology in the Brain of a Harbor Porpoise Exposed to the Cyanobacterial Toxin BMAA
- Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease
- Thermal evaporation as sample preparation for silver-assisted laser desorption/ionization mass spectrometry imaging of cholesterol in amyloid tissues
- Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
- Understanding the mechanisms of disease modifying effects of aerobic exercise in people with Alzheimer's disease
- Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view
- Is Alzheimer disease a disease?
- Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics
- Regulated cell death and its role in Alzheimer's disease and amyotrophic lateral sclerosis
- Local structural preferences in shaping tau amyloid polymorphism
- Association of CSF biomarkers with MRI brain changes in Alzheimer's disease
- Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease
- Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer's Disease
- Innate immune activation in neurodegenerative diseases
- The six brain-specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Transcriptomic evaluation of tau and TDP-43 synergism shows tauopathy predominance and reveals potential modulating targets
- Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis
- Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis
- The proteomic landscape of microglia in health and disease
- Long-Term High-Fat Diet Consumption Aggravates β-Amyloid Deposition and Tau Pathology Accompanied by Microglial Activation in an Alzheimer's Disease Model
- New approach for early and specific Alzheimer disease diagnosis from different plasma biomarkers
- Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy
- Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates
- Neurotoxic Microglial Activation via IFNγ-Induced Nrf2 Reduction Exacerbating Alzheimer's Disease
- NLRP3 inflammasome signalling in Alzheimer's disease
- Extracellular vesicles in heart failure
- Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
- Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
- In vivo PET classification of tau pathologies in patients with frontotemporal dementia
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
- Accumulation of neutral lipids in dystrophic neurites surrounding amyloid plaques in Alzheimer's disease
- Microglial inflammation in genome instability: A neurodegenerative perspective
- Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer's disease and related dementias
- Formation of multiple ion types during MALDI imaging mass spectrometry analysis of Mitragyna speciosa alkaloids in dosed rat brain tissue
- Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
- Lateral geniculate body is spared of tau pathology in Pick disease
- Synaptic adhesion molecule protocadherin-γC5 mediates β-amyloid-induced neuronal hyperactivity and cognitive deficits in Alzheimer's disease
- Synaptic adhesion molecule protocadherin-γC5 mediates β-amyloid-induced neuronal hyperactivity and cognitive deficits in Alzheimer's disease
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Brain hypothyroidism silences the immune response of microglia in Alzheimer's disease animal model
Evidence Blueprint
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
🌐 365 Days
VR Related Evidence Matrix
- Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology
- Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework
- Phosphorylation-state dependent intraneuronal sorting of Aβ differentially impairs autophagy and the endo-lysosomal system
- Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers
- Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer's Disease Brain
- Navigating the Dementia Landscape: Biomarkers and Emerging Therapies
- Vitreous Humor Biomarkers Reflect Pathological Changes in the Brain for Alzheimer's Disease and Chronic Traumatic Encephalopathy
- Integration of Microfluidic Devices with Microelectrode Arrays to Functionally Assay Amyloid-β-Induced Synaptotoxicity
- Mass Spectrometry Reveals that Oxysterols are Secreted from Non-Alcoholic Fatty Liver Disease Induced Organoids
- p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003
- Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection
- Proteomic analysis of the human hippocampus identifies neuronal pentraxin 1 (NPTX1) as synapto-axonal target in late-stage Parkinson's disease
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- Minocycline effects on memory and learning impairment in the beta-amyloid-induced Alzheimer's disease model in male rats using behavioral, biochemical, and histological methods
- Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease
- Proteomics Impact on Cell Biology to Resolve Cell Structure and Function
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology
- Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest
- Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology
- Neuropathology of Alzheimer's Disease
- Remodelling of the cardiac extracellular matrix proteome during chronological and pathological ageing
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Senile plaque-associated transactive response DNA-binding protein 43 in Alzheimer's disease: A case report spanning 16 years of memory loss
- Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease
- Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation
- Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry
- Passive tau-based immunotherapy for tauopathies
- Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer's disease
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity
- Biomarkers associated with the pathogenesis of Alzheimer's disease
- Memantine versus Ginkgo biloba Extract: A Comparative Study on Cognitive Dysfunction Treatment in a Novel Rat Model
- Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model
- Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
- The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease
- Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology
- TDP-43 and Alzheimer's Disease Pathology in the Brain of a Harbor Porpoise Exposed to the Cyanobacterial Toxin BMAA
- Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease
- Thermal evaporation as sample preparation for silver-assisted laser desorption/ionization mass spectrometry imaging of cholesterol in amyloid tissues
- 14-3-3 [Formula: see text]-reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2
- Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
- Understanding the mechanisms of disease modifying effects of aerobic exercise in people with Alzheimer's disease
- A Systematic Review of the Effects of Capsaicin on Alzheimer's Disease
- Establishment of a high-content imaging assay for tau aggregation in hiPSC-derived neurons differentiated from two protocols to routinely evaluate compounds and genetic perturbations
- Virus-induced brain pathology and the neuroinflammation-inflammation continuum: the neurochemists view
- Is Alzheimer disease a disease?
- Pathology of neurodegenerative disease for the general neurologist
- Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics
- Regulated cell death and its role in Alzheimer's disease and amyotrophic lateral sclerosis
- Mass spectrometry in cerebrospinal fluid uncovers association of glycolysis biomarkers with Alzheimer's disease in a large clinical sample
- Retina pathology as a target for biomarkers for Alzheimer's disease: Current status, ophthalmopathological background, challenges, and future directions
- Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology
- Local structural preferences in shaping tau amyloid polymorphism
- Microglial extracellular vesicles induce Alzheimer's disease-related cortico-hippocampal network dysfunction